TCRαβ‑depleted haploidentical stem cell graft with early memory T‑cell donor lymphocyte infusions and selective blinatumomab for pediatric and young adult blood cancers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a phase I prospective study of patients age ≤21 with high‑risk hematologic malignancies who lack a matched sibling or unrelated donor, receiving a TCRαβ‑depleted haploidentical donor product followed by early CD45RA‑depleted donor lymphocyte infusions. Participants receive a defined preparative regimen including rabbit ATG, cyclophosphamide, fludarabine, thiotepa, and melphalan before graft infusion. Selected patients with CD19+ disease may receive blinatumomab in the early post‑transplant period. The primary goal is to test safety and feasibility of early memory T‑cell DLI and to characterize ATG pharmacokinetics; secondary endpoints include safety of adding blinatumomab and immune/clinical outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Recipient:

* Age less than or equal to 21 years
* High risk hematologic malignancy whereas allogeneic transplantation is the current standard of care. This includes (but is not limited to):

  * High risk ALL in CR1 or CR2,
  * any ALL in CR3 or subsequent;
  * AML in high risk CR1 (AML diagnosis includes myeloid sarcoma),
  * any AML in CR2 or subsequent,
  * any therapy related AML;
  * MDS (primary or secondary),
  * NK cell, biphenotypic, or undifferentiated leukemia/lymphoma in CR1 or subsequent;
  * CML in accelerated phase, or in chronic phase with persistent molecular positivity or intolerance to tyrosine kinase inhibitor, or a history of blast crisis.
* If prior CNS leukemia, it must be treated and in CNS CR
* Left ventricular ejection fraction \> 40%, or shortening fraction ≥ 25%
* Creatinine clearance (CrCl) or glomerular filtration rate (GFR) ≥ 50 ml/min/1.73m2
* Forced vital capacity (FVC) ≥ 50% of predicted value; or pulse oximetry ≥ 92% on room air if patient is unable to perform pulmonary function testing
* Karnofsky or Lansky (age dependent) performance score ≥ 50 (See APPENDIX A)
* Bilirubin ≤ 3 times the upper limit of normal for age
* Alanine aminotransferase (ALT) or Aspartate aminotransferase (AST) ≤ 5 times the upper limit of normal for age

Donor:

* At least single haplotype matched (≥ 4 of 8) family member
* At least 18 years of age
* HIV negative
* Regarding donation eligibility, is identified as either:

  * Completed the process of donor eligibility determination as outlined in 21 CFR 1271 and agency guidance; OR
  * Does not meet 21 CFR 1271 eligibility requirements, but has a declaration of urgent medical need completed by the principal investigator or physician sub-investigator per 21 CFR 1271

Exclusion Criteria:

Recipient:

* Has a suitable HLA-identical sibling or suitable 12/12 (HLA-A, B, C, DRB1, DQB1, and DPB1) HLA-matched unrelated donor available in an appropriate time frame.
* Any other active malignancy other than the one for which this HCT is indicated
* Received a prior allogeneic HCT at any time
* Received an autologous HCT within the previous 6 months
* Pregnant, if female is of childbearing potential, negative test must be confirmed by serum or urine pregnancy test within 14 days prior to enrollment
* Breast feeding
* Any current uncontrolled bacterial, fungal or viral infection

Donor:

* Pregnant, negative test must be confirmed by serum or urine pregnancy test within 14 days prior to enrollment if female
* If female, breast feeding

Where it's running

• St. Jude Children's Research Hospital
  Memphis, Tennessee, United States Recruiting

Study contacts

• Principal investigator: Brandon Triplett, MD — St. Jude Children's Research Hospital
• Study coordinator: Brandon Triplett, MD
• Email: referralinfo@stjude.org
• Phone: 8662785833

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• High-dose vs standard-dose flu vaccine in adults with blood cancers on B-cell-depleting therapy

  This study tests whether a high-dose flu shot evokes a stronger immune response than a standard-dose shot in adults with hematologic cancers who recently had B-cell-depleting therapy.

  Recruiting Phase 2 Asan Medical Center · Seoul · NCT07926217

• Blinatumomab plus low-dose donor cells after transplant for high-risk B-ALL

  This small, early-phase study tests whether giving blinatumomab with low-dose donor lymphocytes after allogeneic transplant is safe and helps long-term survival for people with high-risk B-ALL.

  Recruiting Phase 1 Chinese PLA General Hospital · Beijing · NCT07677878

• CD45RA-depleted donor cells to help fight stubborn viral infections after haploidentical transplant

  This trial tests whether giving patients specially prepared donor immune cells (CD45RA-depleted DLI) can help clear viral infections that linger after a stem cell transplant and who have not fully recovered their immunity.

  Recruiting Phase 1/2 Ruijin Hospital · Shanghai, SH · NCT07662369

• LP-118 in combination with standard therapy for newly diagnosed Ph+ ALL

  This study tests whether adding LP-118 to the standard therapy for adults with Philadelphia chromosome–positive ALL is safe and useful.

  Recruiting at 2 sites Phase 1 Wake Forest University Health Sciences · Charlotte, North Carolina and 1 other locations · NCT07614022

• Identifying biomarkers for CAR-T cell therapy in cancer patients

  This study looks at real-world CAR-T therapy in adults with blood cancers to see which biomarkers predict who responds or relapses.

  Recruiting University Hospital, Lille · Lille and 1 other locations · NCT07609485

• QH101 Vδ2 T-cell therapy for adults with relapsed or advanced malignant tumors

  This study will try QH101, an off-the-shelf Vδ2 T-cell therapy, in adults with relapsed or advanced blood cancers or solid tumors to see if it is safe and helps fight tumors.

  Recruiting Phase 1/2 Chinese PLA General Hospital · Beijing, Beijing Municipality · NCT07570563

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.